The Inflation Reduction Act (IRA) of 2022 has been a source of speculation and analysis, making headlines since its passage in Congress. This landmark legislation aims to control national drug spending in the United States by empowering the Centers for Medicare & Medicaid Services (CMS) to negotiate drug prices. As the landscape evolves, understanding the impact on payer strategies, reimbursement models, and patient access is more crucial than ever.

Our white paper, “Navigating the IRA: Key Impacts and Strategies for Market Readiness,” delivers a thorough analysis of these transformative changes and their implications on manufacturers.

Key takeaways:

• Impact of CMS price negotiations and impact on market dynamics
• Implications of CPI-capped price increases on pricing strategies
• Adjusting to the Part D redesign and its financial implications

Empower your organization with the knowledge to navigate the IRA’s complexities and ensure continued access to life-changing medicines.